Metastatic Ewing's sarcoma: Remission induction and survival

F. A. Hayes, E. I. Thompson, L. Parvey, B. Rao, L. Kun, D. Parham, H. O. Hustu

Research output: Contribution to journalArticle

51 Citations (Scopus)

Abstract

Eighteen patients with previously untreated metastatic Ewing's sarcoma (ES) entered a protocol designed to evaluate the response rate to cyclophosphamide and doxorubicin induction therapy delivered before delayed surgery and delayed lower dose, limited-field radiation therapy, (RT), and maintenance chemotherapy. With chemotherapy and delayed surgery, 14 of 18 were rendered free of gross tumor. RT was delivered to the primary site of 11 of these responding patients, plus four of those not free of gross disease. Following RT, two more attained complete clinical remission. Site of primary or metastases did not influence outcome; however, the size of the primary at diagnosis did appear to do so. Ten patients remain disease-free 16 to 82 months (median, 47 months) from diagnosis.

Original languageEnglish (US)
Pages (from-to)1199-1204
Number of pages6
JournalJournal of Clinical Oncology
Volume5
Issue number8
DOIs
StatePublished - Jan 1 1987

Fingerprint

Remission Induction
Ewing's Sarcoma
Radiotherapy
Survival
Maintenance Chemotherapy
Doxorubicin
Cyclophosphamide
Neoplasm Metastasis
Drug Therapy
Neoplasms
Therapeutics

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Hayes, F. A., Thompson, E. I., Parvey, L., Rao, B., Kun, L., Parham, D., & Hustu, H. O. (1987). Metastatic Ewing's sarcoma: Remission induction and survival. Journal of Clinical Oncology, 5(8), 1199-1204. https://doi.org/10.1200/JCO.1987.5.8.1199

Metastatic Ewing's sarcoma : Remission induction and survival. / Hayes, F. A.; Thompson, E. I.; Parvey, L.; Rao, B.; Kun, L.; Parham, D.; Hustu, H. O.

In: Journal of Clinical Oncology, Vol. 5, No. 8, 01.01.1987, p. 1199-1204.

Research output: Contribution to journalArticle

Hayes, FA, Thompson, EI, Parvey, L, Rao, B, Kun, L, Parham, D & Hustu, HO 1987, 'Metastatic Ewing's sarcoma: Remission induction and survival', Journal of Clinical Oncology, vol. 5, no. 8, pp. 1199-1204. https://doi.org/10.1200/JCO.1987.5.8.1199
Hayes FA, Thompson EI, Parvey L, Rao B, Kun L, Parham D et al. Metastatic Ewing's sarcoma: Remission induction and survival. Journal of Clinical Oncology. 1987 Jan 1;5(8):1199-1204. https://doi.org/10.1200/JCO.1987.5.8.1199
Hayes, F. A. ; Thompson, E. I. ; Parvey, L. ; Rao, B. ; Kun, L. ; Parham, D. ; Hustu, H. O. / Metastatic Ewing's sarcoma : Remission induction and survival. In: Journal of Clinical Oncology. 1987 ; Vol. 5, No. 8. pp. 1199-1204.
@article{3fc0e8015fba47c28afcb9bbf1b9a4b7,
title = "Metastatic Ewing's sarcoma: Remission induction and survival",
abstract = "Eighteen patients with previously untreated metastatic Ewing's sarcoma (ES) entered a protocol designed to evaluate the response rate to cyclophosphamide and doxorubicin induction therapy delivered before delayed surgery and delayed lower dose, limited-field radiation therapy, (RT), and maintenance chemotherapy. With chemotherapy and delayed surgery, 14 of 18 were rendered free of gross tumor. RT was delivered to the primary site of 11 of these responding patients, plus four of those not free of gross disease. Following RT, two more attained complete clinical remission. Site of primary or metastases did not influence outcome; however, the size of the primary at diagnosis did appear to do so. Ten patients remain disease-free 16 to 82 months (median, 47 months) from diagnosis.",
author = "Hayes, {F. A.} and Thompson, {E. I.} and L. Parvey and B. Rao and L. Kun and D. Parham and Hustu, {H. O.}",
year = "1987",
month = "1",
day = "1",
doi = "10.1200/JCO.1987.5.8.1199",
language = "English (US)",
volume = "5",
pages = "1199--1204",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "8",

}

TY - JOUR

T1 - Metastatic Ewing's sarcoma

T2 - Remission induction and survival

AU - Hayes, F. A.

AU - Thompson, E. I.

AU - Parvey, L.

AU - Rao, B.

AU - Kun, L.

AU - Parham, D.

AU - Hustu, H. O.

PY - 1987/1/1

Y1 - 1987/1/1

N2 - Eighteen patients with previously untreated metastatic Ewing's sarcoma (ES) entered a protocol designed to evaluate the response rate to cyclophosphamide and doxorubicin induction therapy delivered before delayed surgery and delayed lower dose, limited-field radiation therapy, (RT), and maintenance chemotherapy. With chemotherapy and delayed surgery, 14 of 18 were rendered free of gross tumor. RT was delivered to the primary site of 11 of these responding patients, plus four of those not free of gross disease. Following RT, two more attained complete clinical remission. Site of primary or metastases did not influence outcome; however, the size of the primary at diagnosis did appear to do so. Ten patients remain disease-free 16 to 82 months (median, 47 months) from diagnosis.

AB - Eighteen patients with previously untreated metastatic Ewing's sarcoma (ES) entered a protocol designed to evaluate the response rate to cyclophosphamide and doxorubicin induction therapy delivered before delayed surgery and delayed lower dose, limited-field radiation therapy, (RT), and maintenance chemotherapy. With chemotherapy and delayed surgery, 14 of 18 were rendered free of gross tumor. RT was delivered to the primary site of 11 of these responding patients, plus four of those not free of gross disease. Following RT, two more attained complete clinical remission. Site of primary or metastases did not influence outcome; however, the size of the primary at diagnosis did appear to do so. Ten patients remain disease-free 16 to 82 months (median, 47 months) from diagnosis.

UR - http://www.scopus.com/inward/record.url?scp=0023574820&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023574820&partnerID=8YFLogxK

U2 - 10.1200/JCO.1987.5.8.1199

DO - 10.1200/JCO.1987.5.8.1199

M3 - Article

C2 - 3625245

AN - SCOPUS:0023574820

VL - 5

SP - 1199

EP - 1204

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 8

ER -